Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Award aims to accelerate treatment options in metastatic prostate cancer

Dana-Farber Cancer Institute researchers receive 2021 Movember-Distinguished Gentleman’s Ride-Prostate Cancer Foundation Challenge Award

 

Dana-Farber Cancer Institute researchers are recipients of a new Movember – Prostate Cancer Foundation (PCF) Challenge Award. The $1 million award aims to support ambitious team science with the potential to develop new treatments for metastatic prostate cancer. Dana-Farber’s Matthew Freedman, MD, is principal investigator. Other Dana-Farber team members include Mark Pomerantz, MD, and Sylvan Baca, MD, PhD.

 

There are currently no curative treatment options for prostate cancer that has progressed to a metastatic, treatment-resistant state. Freedman and the team have identified a set of gene transcription regulators that control this progression. They are testing whether these regulators may serve as promising targets for developing new treatments to prevent progression to advanced, lethal prostate cancer. The team is also developing a prostate cancer research resource, which will help other investigators uncover novel biology and treatment opportunities for prostate cancer patients. 

 

The Movember – PCF Challenge Awards, totaling $2 million, are granted to teams at some of the world’s leading cancer research institutions to support cross-disciplinary pioneering research toward the goal of finding cures for prostate cancer. Of these funds, $1.3 million was raised from the 2020 Movember U.S. Campaign and nearly $200,000 came from the 2020 Distinguished Gentleman’s Ride. 

 

 

2021 Movember-Distinguished Gentleman's Ride-PCF Challenge Award  

Principal Investigator: Matthew Freedman, MD (Dana-Farber Cancer Institute, Harvard University). 

Co-Investigators: Mark Pomerantz, MD (Dana-Farber Cancer Institute), Wilbert Zwart, PhD (The Netherlands Cancer Institute), Sylvan Baca, MD, PhD (Dana-Farber Cancer Institute), Tesa Severson, PhD (Netherlands Cancer Institute). 

Project Title: Leveraging Epigenomics to Target Acquired Vulnerabilities in Treatment-Resistant Prostate Cancer  

 

Read more about the 2021 Movember – PCF Challenge Awards: https://www.pcf.org/c/challenge-awards-class-of-2021 

   

 

 

Posted on October 01, 2021

  • Research
  • Mark Pomerantz, MD
  • Matthew Freedman, MD
  • Prostate Cancer

Media Contacts

If you are a journalist and have a question about this story, please call 617-632-4090 and ask to speak to a member of the media team, or email media@dfci.harvard.edu.

The Media Team cannot respond to patient inquiries. For more information, please see Contact Us.

Prostate Cancer Cells